AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:14PM BST
| Previous close | 147.37 |
| Open | 150.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 146.93 - 147.40 |
| 52-week range | 146.93 - 147.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.191B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | 6.97 |
| Earnings date | 27 Oct 2022 - 31 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?
Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.
- Globe Newswire
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseasesSosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2
- Simply Wall St.
With EPS Growth And More, AbbVie (NYSE:ABBV) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
© 2022 Yahoo. All rights reserved.
